{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:17:15Z","timestamp":1787008635220,"version":"build-2736575974"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,2,3]],"date-time":"2018-02-03T00:00:00Z","timestamp":1517616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01 AI106499"],"award-info":[{"award-number":["U01 AI106499"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068619"],"award-info":[{"award-number":["UM1 AI068619"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01 AI064002"],"award-info":[{"award-number":["U01 AI064002"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R03 AI120819"],"award-info":[{"award-number":["R03 AI120819"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R03 AI122908"],"award-info":[{"award-number":["R03 AI122908"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Academy for Advancing Translational Science","award":["UL1 TR000004"],"award-info":[{"award-number":["UL1 TR000004"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7,18]]},"DOI":"10.1093\/cid\/ciy083","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T15:10:19Z","timestamp":1517497819000},"page":"411-419","source":"Crossref","is-referenced-by-count":69,"title":["Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine"],"prefix":"10.1093","volume":"67","author":[{"given":"David V","family":"Glidden","sequence":"first","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Mulligan","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"McMahan","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L","family":"Anderson","sequence":"additional","affiliation":[{"name":"University of Colorado, Denver, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Guanira","sequence":"additional","affiliation":[{"name":"Investigaciones M\u00e9dicas en Salud, Lima, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suwat","family":"Chariyalertsak","sequence":"additional","affiliation":[{"name":"Research Institute for Health Sciences, Chiang Mai University, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan P","family":"Buchbinder","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"},{"name":"Bridge HIV, San Francisco Department of Public Health, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda-Gail","family":"Bekker","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"},{"name":"Desmond Tutu HIV Foundation, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Schechter","sequence":"additional","affiliation":[{"name":"Projeto Pra\u00e7a Onze, Hospital Escola S\u00e3o Francisco de Assis and Universidade Federal do Rio de Janeiro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Grinsztejn","sequence":"additional","affiliation":[{"name":"Evandro Chagas National Institute of Infectious Diseases-Fiocruz, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M","family":"Grant","sequence":"additional","affiliation":[{"name":"Gladstone Institute of Virology, California"},{"name":"San Francisco AIDS Foundation, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,2,3]]},"reference":[{"key":"key\n\t\t\t\t20180718010106_CIT0001","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180718010106_CIT0002","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"Baeten","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180718010106_CIT0003","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana","volume":"367","author":"Thigpen","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180718010106_CIT0004","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","article-title":"Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"381","author":"Choopanya","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180718010106_CIT0005","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-demand preexposure prophylaxis in men at high risk for HIV-1 infection","volume":"373","author":"Molina","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180718010106_CIT0006","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial","volume":"387","author":"McCormack","year":"2016","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180718010106_CIT0007","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S1473-3099(14)70847-3","article-title":"Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study","volume":"14","author":"Grant","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180718010106_CIT0008","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/QAI.0000000000001179","article-title":"An HIV preexposure prophylaxis demonstration project and safety study for young MSM","volume":"74","author":"Hosek","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180718010106_CIT0009","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/jamainternmed.2015.4683","article-title":"Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services","volume":"176","author":"Liu","year":"2016","journal-title":"JAMA Intern Med"},{"key":"key\n\t\t\t\t20180718010106_CIT0010","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/cid\/civ778","article-title":"No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting","volume":"61","author":"Volk","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180718010106_CIT0011","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1097\/QAD.0000000000001519","article-title":"Medication adherence, condom use and sexually transmitted infections in Australian PrEP users: interim results from the Victorian PrEP Demonstration Project","volume":"31","author":"Lal","year":"2017","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180718010106_CIT0012","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s10461-016-1627-z","article-title":"Values and preferences on the use of oral pre-exposure prophylaxis (PrEP) for HIV prevention among multiple populations: a systematic review of the literature","volume":"21","author":"Koechlin","year":"2017","journal-title":"AIDS Behav"},{"key":"key\n\t\t\t\t20180718010106_CIT0013","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/jac\/dkn251","article-title":"HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options","volume":"62","author":"Mallewa","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180718010106_CIT0014","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","article-title":"Cardiovascular risk and body-fat abnormalities in HIV-infected adults","volume":"352","author":"Grinspoon","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180718010106_CIT0015","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180718010106_CIT0016","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1310\/hct0906-407","article-title":"Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study)","volume":"9","author":"Ribera","year":"2008","journal-title":"HIV Clin Trials"},{"key":"key\n\t\t\t\t20180718010106_CIT0017","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1310\/hct0806-381","article-title":"The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy","volume":"8","author":"Madruga","year":"2007","journal-title":"HIV Clin Trials"},{"key":"key\n\t\t\t\t20180718010106_CIT0018","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/135965350701200301","article-title":"The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients","volume":"12","author":"Milinkovic","year":"2007","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180718010106_CIT0019","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/QAI.0b013e3181ae2eb9","article-title":"A randomized comparative trial of continued zidovudine\/lamivudine or replacement with tenofovir disoproxil fumarate\/emtricitabine in efavirenz-treated HIV-1-infected individuals","volume":"51","author":"Fisher","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180718010106_CIT0020","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1097\/01.aids.0000247574.33998.03","article-title":"A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy","volume":"20","author":"Moyle","year":"2006","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180718010106_CIT0021","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1089\/apc.2012.0419","article-title":"From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City","volume":"27","author":"Golub","year":"2013","journal-title":"AIDS Patient Care STDS"},{"key":"key\n\t\t\t\t20180718010106_CIT0022","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/cid\/civ324","article-title":"Effects of emtricitabine\/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial","volume":"61","author":"Mulligan","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180718010106_CIT0023","doi-asserted-by":"crossref","first-page":"151ra125","DOI":"10.1126\/scitranslmed.3004006","article-title":"Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men","volume":"4","author":"Anderson","year":"2012","journal-title":"Sci Transl Med"},{"key":"key\n\t\t\t\t20180718010106_CIT0024","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511754098","volume-title":"Quantile regression","author":"Koenker","year":"2005"},{"key":"key\n\t\t\t\t20180718010106_CIT0025","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4614-1353-0","volume-title":"Regression methods in biostatistics","author":"Vittinghoff","year":"2012"},{"key":"key\n\t\t\t\t20180718010106_CIT0026","volume-title":"StataCorp","year":"2014"},{"key":"key\n\t\t\t\t20180718010106_CIT0027","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3851\/IMP1518","article-title":"The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers","volume":"15","author":"Randell","year":"2010","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180718010106_CIT0028","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1097\/QAD.0b013e32833ad8b4","article-title":"A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206","volume":"24","author":"Tungsiripat","year":"2010","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180718010106_CIT0029","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/cid\/civ296","article-title":"The lipid-lowering effect of tenofovir\/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial","volume":"61","author":"Santos","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180718010106_CIT0030","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180718010106_CIT0031","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(15)00348-5","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study","volume":"16","author":"Mills","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180718010106_CIT0032","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/QAI.0000000000001186","article-title":"Brief report: switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected adults with renal impairment: 96-week results from a single-arm, multicenter, open-label phase 3 study","volume":"74","author":"Post","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180718010106_CIT0033","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3945\/ajcn.2008.26147","article-title":"Fifteen-year longitudinal trends in walking patterns and their impact on weight change","volume":"89","author":"Gordon-Larsen","year":"2009","journal-title":"Am J Clin Nutr"},{"key":"key\n\t\t\t\t20180718010106_CIT0034","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/sj.ijo.0802263","article-title":"Rates of weight change for black and white Americans over a twenty year period","volume":"27","author":"Sheehan","year":"2003","journal-title":"Int J Obes Relat Metab Disord"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/67\/3\/411\/25156350\/ciy083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T15:41:08Z","timestamp":1660405268000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/67\/3\/411\/4836821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,3]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,2,3]]},"published-print":{"date-parts":[[2018,7,18]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy083","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,8,1]]},"published":{"date-parts":[[2018,2,3]]}}}